[go: up one dir, main page]

UA84402C2 - Use of carbon monoxide for treatment of nephritis - Google Patents

Use of carbon monoxide for treatment of nephritis

Info

Publication number
UA84402C2
UA84402C2 UA20041210106A UA20041210106A UA84402C2 UA 84402 C2 UA84402 C2 UA 84402C2 UA 20041210106 A UA20041210106 A UA 20041210106A UA 20041210106 A UA20041210106 A UA 20041210106A UA 84402 C2 UA84402 C2 UA 84402C2
Authority
UA
Ukraine
Prior art keywords
carbon monoxide
nephritis
treatment
biomarker
spleen
Prior art date
Application number
UA20041210106A
Other languages
Russian (ru)
Ukrainian (uk)
Inventor
Августин М.К. Чой
Лео Е. Оттербейн
Original Assignee
Йельский Университет
Джонс Хопкинс Юниверсити
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Йельский Университет, Джонс Хопкинс Юниверсити filed Critical Йельский Университет
Publication of UA84402C2 publication Critical patent/UA84402C2/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K33/00—Medicinal preparations containing inorganic active ingredients
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K33/00—Medicinal preparations containing inorganic active ingredients
    • A61K33/44—Elemental carbon, e.g. charcoal, carbon black
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]

Landscapes

  • Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Epidemiology (AREA)
  • Inorganic Chemistry (AREA)
  • Rheumatology (AREA)
  • Immunology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Urology & Nephrology (AREA)
  • Pulmonology (AREA)
  • Hospice & Palliative Care (AREA)
  • Psychology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Pain & Pain Management (AREA)
  • Psychiatry (AREA)
  • Dermatology (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Investigating Or Analysing Biological Materials (AREA)

Abstract

The present invention relates to the use of carbon monoxide (CO) as a biomarker and therapeutic agent of heart, long, liver, spleen, brain, skin and kidney diseases and other conditions and disease states.
UA20041210106A 2002-05-09 2002-05-09 Use of carbon monoxide for treatment of nephritis UA84402C2 (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
PCT/US2002/014836 WO2003094932A1 (en) 2002-05-09 2002-05-09 Carbon monoxide as a biomarker and therapeutic agent

Publications (1)

Publication Number Publication Date
UA84402C2 true UA84402C2 (en) 2008-10-27

Family

ID=29418043

Family Applications (1)

Application Number Title Priority Date Filing Date
UA20041210106A UA84402C2 (en) 2002-05-09 2002-05-09 Use of carbon monoxide for treatment of nephritis

Country Status (13)

Country Link
EP (1) EP1501523A4 (en)
JP (1) JP2005532314A (en)
KR (1) KR20040106515A (en)
CN (1) CN1638781A (en)
AU (1) AU2002308676B2 (en)
BR (1) BR0215717A (en)
CA (1) CA2484770A1 (en)
EA (1) EA200401478A1 (en)
MX (1) MXPA04011113A (en)
NO (1) NO20044865L (en)
RS (1) RS96904A (en)
UA (1) UA84402C2 (en)
WO (1) WO2003094932A1 (en)

Families Citing this family (35)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7678390B2 (en) 1999-04-01 2010-03-16 Yale University Carbon monoxide as a biomarker and therapeutic agent
GB0111872D0 (en) 2001-05-15 2001-07-04 Northwick Park Inst For Medica Therapeutic agents and methods
EP1476168A2 (en) 2002-02-04 2004-11-17 ALFAMA-Investigacao e Desenvolvimento de Produtos Farmaceuticos Lda. Use of co-releasing compounds for the manufacture of a medicament for the treatment of inflammatory diseases
EA200401365A1 (en) 2002-04-15 2005-04-28 Юниверсити Оф Питтсбург Оф Дзе Коммонвелт Систем Оф Хайер Эдьюкейшн METHODS OF TREATMENT OF ILEUS
JP4585765B2 (en) 2002-04-15 2010-11-24 ユニバーシティ オブ ピッツバーグ オブ ザ コモンウェルス システム オブ ハイヤー エデュケイション How to treat necrotizing enterocolitis
ES2372273T3 (en) * 2002-05-17 2012-01-17 Yale University METHODS OF TREATMENT OF HEPATITIS.
JP2005345242A (en) * 2004-06-02 2005-12-15 Tohoku Univ Methods for evaluating the efficacy of chemotherapy for lung cancer
WO2007073005A1 (en) * 2005-12-22 2007-06-28 Keio University Regulator of methyl transfer reaction
WO2008069688A2 (en) * 2006-12-06 2008-06-12 Alfama - Investigação E Desenvolvimento De Produtos Farmacêuticos Lda Methods for treating inflammatory disease by administering aldehydes and derivatives thereof
JP2010094122A (en) 2008-06-12 2010-04-30 Keio Gijuku Diagnosis-treatment option for head-and-neck tumor using micro-rna as biomarker
JP2012046470A (en) * 2010-08-30 2012-03-08 Japan Science & Technology Agency Enzyme activity inhibitor for gapdh
EP2663193B1 (en) * 2011-01-14 2019-05-08 Children's Hospital Los Angeles Solution of carbon monoxide for treatment of disease, including sickle cell disease
US8927750B2 (en) 2011-02-04 2015-01-06 Universitaet Zu Koeln Acyloxy- and phosphoryloxy-butadiene-Fe(CO)3 complexes as enzyme-triggered co-releasing molecules
US9359197B2 (en) 2011-03-24 2016-06-07 Technion Research & Development Foundation Ltd. Method of diagnosing, prognosing and monitoring parkinson's disease
WO2012145520A2 (en) 2011-04-19 2012-10-26 Alfama, Inc. Carbon monoxide releasing molecules and uses thereof
WO2013013179A1 (en) 2011-07-21 2013-01-24 Alfama, Inc. Ruthenium carbon monoxide releasing molecules and uses thereof
US10031126B2 (en) 2013-04-04 2018-07-24 The Regents Of The University Of California System and method for utilizing exhaled breath for monitoring inflammatory states
EP2868348A1 (en) * 2013-11-04 2015-05-06 Universität Zürich CO-releasing compounds & formulations thereof useful for inducing mitochondrial biogenesis and tissue repair
TW201618795A (en) * 2014-04-15 2016-06-01 波泰里斯股份有限公司 Systems and methods to improve organ function and organ transplant longevity
JP7161737B2 (en) * 2017-01-30 2022-10-27 哲也 石川 Methods for testing malignant tumors
CN112236150A (en) 2018-06-08 2021-01-15 住友精化株式会社 Composition for inflammatory digestive disease
CN112272559A (en) * 2018-06-08 2021-01-26 住友精化株式会社 Composition for skin wound
WO2020247825A1 (en) * 2019-06-06 2020-12-10 The General Hospital Corporation Carbon monoxide as a treatment for neurodegenerative disease
WO2022015986A1 (en) * 2020-07-16 2022-01-20 Cornell University Methods for treating metastatic cancer using low dose carbon monoxide
US11932080B2 (en) 2020-08-20 2024-03-19 Denso International America, Inc. Diagnostic and recirculation control systems and methods
US12377711B2 (en) 2020-08-20 2025-08-05 Denso International America, Inc. Vehicle feature control systems and methods based on smoking
US11760169B2 (en) 2020-08-20 2023-09-19 Denso International America, Inc. Particulate control systems and methods for olfaction sensors
US11881093B2 (en) 2020-08-20 2024-01-23 Denso International America, Inc. Systems and methods for identifying smoking in vehicles
US11760170B2 (en) 2020-08-20 2023-09-19 Denso International America, Inc. Olfaction sensor preservation systems and methods
US12251991B2 (en) 2020-08-20 2025-03-18 Denso International America, Inc. Humidity control for olfaction sensors
US11636870B2 (en) 2020-08-20 2023-04-25 Denso International America, Inc. Smoking cessation systems and methods
US12017506B2 (en) 2020-08-20 2024-06-25 Denso International America, Inc. Passenger cabin air control systems and methods
US11828210B2 (en) 2020-08-20 2023-11-28 Denso International America, Inc. Diagnostic systems and methods of vehicles using olfaction
US11813926B2 (en) 2020-08-20 2023-11-14 Denso International America, Inc. Binding agent and olfaction sensor
US12269315B2 (en) 2020-08-20 2025-04-08 Denso International America, Inc. Systems and methods for measuring and managing odor brought into rental vehicles

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5293875A (en) * 1992-06-16 1994-03-15 Natus Medical Incorporated In-vivo measurement of end-tidal carbon monoxide concentration apparatus and methods
DE4421433C1 (en) * 1994-06-18 1995-06-08 Lohmann Therapie Syst Lts Transdermal therapeutic system for treatment of, e.g., hypertension
ATE253372T1 (en) * 1996-08-27 2003-11-15 Messer Griesheim Gmbh HYDROGEN CONTAINING MEDICATION
EP1381354A2 (en) * 2001-03-30 2004-01-21 Sangstat Medical Corporation Carbon monoxide generating compounds for treatment of vascular, inflammatory and immune disorders

Also Published As

Publication number Publication date
MXPA04011113A (en) 2005-02-14
JP2005532314A (en) 2005-10-27
EP1501523A4 (en) 2006-12-13
EA200401478A1 (en) 2005-12-29
CN1638781A (en) 2005-07-13
AU2002308676B2 (en) 2009-06-11
EP1501523A1 (en) 2005-02-02
CA2484770A1 (en) 2003-11-20
WO2003094932A1 (en) 2003-11-20
AU2002308676A1 (en) 2003-11-11
BR0215717A (en) 2005-02-22
RS96904A (en) 2007-02-05
KR20040106515A (en) 2004-12-17
NO20044865L (en) 2004-12-07

Similar Documents

Publication Publication Date Title
UA84402C2 (en) Use of carbon monoxide for treatment of nephritis
WO2004078124A3 (en) Methods and compositions involving mda-7
DK1530724T3 (en) Diagnosis and prevention of cancer cell invasion
PH12015501744B1 (en) Therapeutic and diagnostic target for cancer comprising dll3 binding reagents
SI2527315T1 (en) Compounds, compositions and methods for the treatment of amyloid diseases and synucleinopathies such as Alzheimer's disease, type 2 diabetes and Parkinson's disease
BR0316438A (en) Erythropoietin use in heart disease
SG149063A1 (en) Use of modified cyclosporins for the treatment of hcv disorders
EP1553912A4 (en) Compositions and methods for the diagnosis and treatment of tumor
TW200509892A (en) Novel aminobenzophenone compounds
WO2006050389A3 (en) Pyridazine compounds, compositions and methods
IL162201A0 (en) New methods for diagnosis and treatment of tumours
NO20076241L (en) Vascular disease therapies
UA83691C2 (en) Use of substituted 2-aminotetralines for the preventative treatment of parkinson's disease
YU33203A (en) Radiopharmaceuticals for diagnosing alzheimer's disease
EP1636160A4 (en) Novel therapeautic agents for the treatment of cancer, metabolic diseases and skin disorders
ZA200510282B (en) Compositions and methods for the diagnosis and treatment of tumor
MXPA05003818A (en) Gene expression profiling from ffpe samples.
AU2003237792A8 (en) Compositions and methods for the diagnosis and treatment of tumor
NZ546440A (en) Treatment of inflammatory bowel disease with 2-methylene-19-nor-vitamin D compounds
WO2004047757A3 (en) Diagnosing and treating hematopoietic cancers
WO2007031878A3 (en) Methods of treating nervous disorders
SI1596879T1 (en) Use of kahalalide compounds for the manufacture of a medicament for the treatment of psoriasis
WO2005022164A3 (en) Diagnostics and therapeutics for diseases associated with kallikrein 8 (klk8)
WO2006050359A3 (en) Pyridazine compounds and methods
WO2004016813A3 (en) Hnf1 alpha as a tumor suppressor gene, and diagnostic and therapeutic applications thereof